Ribonexus
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ribonexus - overview
Location
-, Villejuif, France
Primary Industry
Biotechnology
About
Based in France, Aglaia Therapeutics operates as a biotechnology company that creates medicines for cancer patients who are receiving targeted therapy. The company was co-founded by Advent France Biotechnology, Alejo Chorny, and Institut Curie, and Gustave Roussy. In September 2021, Aglaia Therapeutics raised its latest Seed funding from a group of investors that includes Advent France Biotechnology, Crédit Mutuel Innovation, and Pierre Fabre. The company offers oncology therapies that aim to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who develop resistance to these kinds of treatments.
The therapy targets mRNA translation through an acquisition of a product from Pierre Fabre. The company plans to use the latest Seed funding to prepare its preclinical development program.
Current Investors
Credit Mutuel Equity, Pierre Fabre, AdBio Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.